In conclusion, outcomes among patients with TP53MUT AML after intensive therapy and allo-HCT remain poor; however, patients with low TP53 VAF at the time of diagnosis may still benefit from transplantation. This evidence concerns the gene TP53 and acute myeloid leukemia.